All In Biotech

Drug Trial Radar · NCT06605222

A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors

A Phase I/II, Open Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-7787 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

201

Planned (sponsor's estimate)

Start

Oct 4, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Sep 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-7787 injection monotherapy for patients with advanced solid tumors. To explore the reasonable dosage of SHR-7787 injection monotherapy for patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • SHR-7787 injectionDrug

    Firstly Dose Escalation and Dose Expansion of SHR-7787 injection monotherapy should be conducted.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated doseTime frame: first dose of study medication up to 21 days
  2. Recommended phase II doseTime frame: first dose of study medication up to 21 days
  3. Incidence and severity of adverse events (AEs)/serious adverse events (SAEs)Time frame: from signature completion of ICF to 60 days after the last dose or to the beginning of the new anti-cancer therapy, whichever came first, assessed up to 24 weeks
  4. Incidence of Dose Limited Toxicity (DLT)Time frame: from first dose to 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.